Suppr超能文献

正常受试者中因子 VII 及对去氨基-8-D-精氨酸加压素的纤溶反应,以及血友病和血管性血友病患者中的分离反应。

Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease.

作者信息

Ludlam C A, Peake I R, Allen N, Davies B L, Furlong R A, Bloom A L

出版信息

Br J Haematol. 1980 Jul;45(3):499-511. doi: 10.1111/j.1365-2141.1980.tb07169.x.

Abstract

Deamino-8-D-argenine vasopressin (DDAVP) was given by intravenous infusion to normal subjects, haemophiliacs and patients with von Willebrand's disease (vWd) and the factor VIII and plasminogen activator response was studied. In normal subjects and most patients with mild haemophilia and mild (intermediate) von Willebrand's disease there was an increase in plasminogen activator and all factor VIII related activities. In patients with mild vWd the prolonged bleeding time was shortened by DDAVP despite only a modest rise in factor VIII related Ristocetin cofactor activity (VIIIR:RiCoF). Sub-groups of patients have been characterized in whom atypical responses was observed. In two brothers with clinically severe haemophilia, but with 5--6 u/dl procoagulant factor VIII (VIIIC), there was an increase in VIIIC but no rise of the corresponding antigen, suggesting increased release of an antigenically abnormal poorly functioning molecule. A patient with intermediate vWd was studied in whom neither DDAVP, adrenaline infusion, nor venous occlusion resulted in an increase in either plasminogen activator or factor VIII related antigen (VIIRAg), although there was a significant increase in VIIIC. In a further patient with severe vWd, DDAVP failed to elicit any plasminogen activator or VIII response. The results obtained from these two patients suggested that in some individuals the presumed endothelial cell abnormality in vWd may be more extensive than a defect in VIIIRAg synthesis. Sub-groups of patients have been identified for whom treatment with factor VIII concentrates would be more appropriate than DDAVP prior to minor surgery.

摘要

将去氨基 - 8 - D - 精氨酸加压素(DDAVP)静脉输注给正常受试者、血友病患者和血管性血友病(vWd)患者,并研究了因子VIII和纤溶酶原激活物的反应。在正常受试者以及大多数轻度血友病患者和轻度(中度)血管性血友病患者中,纤溶酶原激活物和所有与因子VIII相关的活性均有所增加。在轻度vWd患者中,尽管与因子VIII相关的瑞斯托霉素辅因子活性(VIIIR:RiCoF)仅适度升高,但DDAVP仍缩短了延长的出血时间。已对观察到非典型反应的患者亚组进行了特征描述。在两名临床诊断为重度血友病但凝血因子VIII(VIIIC)水平为5 - 6 u/dl的兄弟中,VIIIC增加,但相应抗原未升高,提示释放了抗原异常且功能不良的分子。对一名中度vWd患者进行了研究,其中DDAVP、肾上腺素输注或静脉闭塞均未导致纤溶酶原激活物或与因子VIII相关的抗原(VIIRAg)增加,尽管VIIIC有显著增加。在另一名重度vWd患者中,DDAVP未能引发任何纤溶酶原激活物或VIII反应。从这两名患者获得的结果表明,在某些个体中,vWd中推测的内皮细胞异常可能比VIIIRAg合成缺陷更为广泛。已确定了一些患者亚组,对于他们而言,在进行小手术前,使用因子VIII浓缩物治疗比DDAVP更为合适。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验